Biogenics Research Institute & Biogenics Research Chamber, 8229 Fredericksburg Road, San Antonio, TX, USA.
Expert Rev Clin Immunol. 2011 Nov;7(6):735-41. doi: 10.1586/eci.11.70.
Allergic rhinitis is considered one of the most common afflictions of humans, affecting up to 30% of the world's population, and is increasing in incidence. Primary symptoms, comorbid conditions and complications of this disorder exact a significant toll, resulting in an enormous physical, social and economic impact on society. Single-season allergic rhinitis accounts for approximately 20% of cases of allergic rhinitis with another 40% having mixed seasonal-perennial presentations. Management of this disorder encompasses several treatment options, with intranasal corticosteroids recommended as first-line treatment in moderate-to-severe seasonal allergic rhinitis in current practice parameters. Ciclesonide is the most recently approved product in this category for the management of seasonal allergic rhinitis and is the subject of this article.
变应性鼻炎被认为是人类最常见的疾病之一，影响了多达 30%的世界人口，且发病率呈上升趋势。这种疾病的主要症状、合并症和并发症造成了重大的损失，给社会带来了巨大的身体、社会和经济影响。单季变应性鼻炎约占变应性鼻炎病例的 20%，另有 40%的患者呈混合季节性-常年性表现。这种疾病的治疗包括几种治疗选择，目前的实践参数建议中重度季节性变应性鼻炎的一线治疗药物为鼻内皮质类固醇。环索奈德是该类别中最近批准用于季节性变应性鼻炎治疗的药物，是本文的主题。
